Cefiderocol in Difficult-to-Treat non-fermenting Gram-negative bacteria (Nf-GNB) in ICU Settings
An erratum to this article was published (Ann Intensive Care, 24 May 2024 ↗)
Authors' conclusion
Cefiderocol did not show an improvement in clinical cure or mortality rates compared to BAT in the treatment of DTR Nf-GNB, but it was associated with a higher relapse rate.
Study context
- Population
- Adult ICU patients (9 ICUs incl. a burn ICU, 2019–2023) with difficult-to-treat resistance non-fermenting Gram-negative bacteria isolated from blood or lungs1:2 matched
- Participants
- 27 vs 54
- Exposure
- Cefiderocol vs best available therapy
- Cefiderocoln = 27
- Best Available Therapy (BAT)n = 54reference
- Outcome
- Clinical cure
- Follow-up
- 15 days
Methodological detailsmulticentre (9 ICUs), Four patients not exactly matched on ICU type
- Multicentre (9 ICUs)
- Four patients not exactly matched on ICU type
Main finding
As reported in the abstract
Clinical cure at 15 days
- Clinical cure at 15 days comparable between groups
- Matched cohort
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Cefiderocol | BAT | aOR (CI) | |
|---|---|---|---|---|
| Relapse | 29.6% | 7.4% | 10.06 (1.96–51.53) | |
| 0.050.21520Adjusted odds ratio (log scale) |
Clinical cure at 30 days and in-ICU mortality
- Comparable between groups
Original publication
Cefiderocol in Difficult-to-Treat Nf-GNB in ICU Settings. Ann Intensive Care. Published 12 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →